Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone45-7020-2728
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$479.45 million
Profitability
Miscellaneous
Employees377
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions
What is Genmab A/S's stock symbol?
Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."
How were Genmab A/S's earnings last quarter?
Genmab A/S (OTCMKTS:GNMSF) announced its earnings results on Wednesday, August, 14th. The company reported $0.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.36 by $0.16. The business had revenue of $116.49 million for the quarter, compared to analyst estimates of $129.17 million. Genmab A/S had a return on equity of 14.32% and a net margin of 36.67%. View Genmab A/S's Earnings History.
When is Genmab A/S's next earnings date?
Has Genmab A/S been receiving favorable news coverage?
News coverage about GNMSF stock has been trending neutral this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genmab A/S earned a news impact score of 0.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Genmab A/S.
Who are some of Genmab A/S's key competitors?
Some companies that are related to Genmab A/S include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of Genmab A/S own?
Who are Genmab A/S's key executives?
Genmab A/S's management team includes the folowing people:
- Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 58)
- Mr. David A. Eatwell, Exec. VP & CFO (Age 58)
- Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)
- Ms. Jane Juel, Sr. Director of Operations & Resource Management
- Mr. Peter Ros, Sr. Director of Fin. & Accounting
How do I buy shares of Genmab A/S?
Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genmab A/S's stock price today?
One share of GNMSF stock can currently be purchased for approximately $204.00.
How big of a company is Genmab A/S?
Genmab A/S has a market capitalization of $12.58 billion and generates $479.45 million in revenue each year. The company earns $233.19 million in net income (profit) each year or $3.76 on an earnings per share basis. Genmab A/S employs 377 workers across the globe.View Additional Information About Genmab A/S.
What is Genmab A/S's official website?
How can I contact Genmab A/S?
Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]
MarketBeat Community Rating for Genmab A/S (OTCMKTS GNMSF)
MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
